Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aclaris Therapeutics, Inc.

NASDAQ: ACRS · Life Sciences · 5 alerts · CIK 1557746

Aclaris Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.61Close, Nov 16
Market cap
$572M
Shares outstanding
158.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aclaris Therapeutics, Inc. filings on SEC EDGAR ↗

4:35 PM ET 10-Q
Financial Results

Aclaris Therapeutics Q3 2026 Results: Net Loss of $18.5M, Loss Widens

Aclaris Therapeutics reported a net loss of $59.8 million for the nine months ended September 30, 2026, compared to $45.1 million for the same period in 2025. The company significantly increased its cash position through at-the-market sales of common stock, raising approximately $116.2 million in net proceeds during the first nine months of 2026.

Key figure
Net loss $18.5M
7:16 AM ET 8-K
Financial Results

Aclaris Therapeutics Financial Results

Aclaris Therapeutics reported its Q3 2026 financial results, highlighting a cash position of $156.4M which is expected to fund operations through the first half of 2029. The company also provided clinical updates, including positive Phase 1b data for ATI-052 in atopic dermatitis and asthma, and the planned initiation of a Phase 2b trial for modzatinib in the fourth quarter of 2026.

Term
Q3 2026

“Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective.”

Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.